Hypertension, hypertensive heart disease and heart failure. Role of loop diuretics;Hipertensión arterial, cardiopatía hipertensiva e insuficiencia cardíaca. Papel de los diuréticos de asa

Medicina Clinica

Volumn 131, Issue 17, 2008, Pages 660-664

  Anguita, Manuel ^a   Toledano, Francisco ^a   León, Carmen ^a   Castillo, Juan C ^a  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DIURETIC AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; LOOP DIURETIC AGENT; LOSARTAN; SULFONAMIDE; TORASEMIDE;

ARTICLE; ELECTROCARDIOGRAPHY; HEART FAILURE; HEART MUSCLE CONTRACTILITY; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; CLINICAL TRIAL; COMPARATIVE STUDY; DOPPLER ECHOCARDIOGRAPHY; HEART LEFT VENTRICLE HYPERTROPHY; HEART STROKE VOLUME; META ANALYSIS; REVIEW; RISK FACTOR;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CLINICAL TRIALS AS TOPIC; DIURETICS; ECHOCARDIOGRAPHY, DOPPLER; FUROSEMIDE; HEART FAILURE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; LOSARTAN; META-ANALYSIS AS TOPIC; RISK FACTORS; SODIUM POTASSIUM CHLORIDE SYMPORTER INHIBITORS; STROKE VOLUME; SULFONAMIDES;

EID: 60849105992     PISSN: 00257753     EISSN: 15788989     Source Type: Journal    
DOI: 10.1157/13128726     Document Type: Article

References (35)

1. Yusuf S., and Abbot R.A. Changes in hypertension treatment and in congestive heart failure in the United States. Hypertension 13 Suppl 1 (1989) 74-79
2. Levy D., Larson M.G., Vasan R.S., Hannel W.B., and Ho K.K.L. The progression from hypertension to congestive heart failure. JAMA 275 (1996) 1557-1562
3. Kannel W.B., Dannenberg A.L., and Levy D. Population implications of electrocardiographic left ventricular hypertrophy. Am J Cardiol 60 (1987) 185-193
4. Ren J., Pancholi S.B., and Iskandrian A.S. Doppler echocardiographic evaluation of the spectrum of left ventricular diastolic dysfunction in essential hypertension. Am Heart J 127 (1994) 906-913
5. The NETWORK Investigators. Clinical outcome with enalapril in symptomatic heart failure: a dose comparison. Eur Heart J 19 (1998) 481-489
6. Cutler J.A., Psaty B.M., MacMahon S., and Furberg C. Public health issues in hypertension control: what has been learned from clinical trials. In: Laragh J.H., and Brenner B.M. (Eds). Hypertension: pathophysiology, diagnosis and treatment (1995), Raven Press, New York 253-270
7. Moser M., and Herbert P.R. Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension tretment trials. J Am Coll Cardiol 27 (1996) 1214-1218
8. Hansson L., Lindholm L.H., Niskanen L., Lanke J., Hedner T., Niklason A., et al. Effect of angiotensin converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension. The CAPP randomised trail. Lancet 353 (1999) 611-616
9. Anguita M., Castillo J.C., Ramírez A., Siles J.R., Ojeda S., Mesa D., et al. Insuficiencia cardíaca debida a disfunción ventricular sistólica severa de origen hipertensivo. Evolución clínica y funcional a largo plazo. Rev Esp Cardiol 53 (2000) 927-931
10. Anguita M., Rodríguez M., Ojeda S., Ruiz M., Romo E., Mesa D., et al. Evolución clínica y reversibilidad de la disfunción sistólica en pacientes con miocardiopatía dilatada hipertensiva e insuficiencia cardíaca crónica. Rev Esp Cardiol 57 (2004) 834-841
11. González-Juanatey J.R., Alegría E., Vidal J.V., Caro J.L., García-Acuña J., and González-Maqueda I. Impacto de la hipertensión en las cardiopatías en España: estudio CARDIOTENS 1999. Rev Esp Cardiol 54 (2001) 139-149
12. Varela-Román A., González-Juanatey J.R., Basante P., Trillo R., García-Seara J., Martínez-Sande J.L., et al. Clinical characteristics and prognosis of hospitalized inpatients with heart failure and preserved or reduced left ventricular ejection fraction. Heart 88 (2002) 249-254
13. Ojeda S., Anguita M., Muñoz J.F., Rodríguez M.T., Mesa D., Franco M., et al. Características clínicas y pronóstico a medio plazo de la insuficiencia cardíaca con función sistólica conservada. ¿Es diferente de la insuficiencia cardíaca sistólica?. Rev Esp Cardiol 56 (2003) 1050-1056
14. Anguita M., and los investigadores del Registro BADAPIC. Características clínicas, tratamiento y morbimortalidad a corto y largo plazo de pacientes con insuficiencia cardíaca controlados en consultas específicas de insuficiencia cardíaca. Resultados del Registro BADAPIC. Rev Esp Cardiol 57 (2004) 1159-1169
15. McDermott M.M., Feinglass S., and Sy J. Hospitalized congestive heart failure patients with preserved versus abnormal left ventricular systolic function: clinical characteristics and drug therapy. Am J Med 99 (1995) 629-635
16. Zile M.R., and Brutsaert D.L. New concepts in diastolic function and diastolic heart failure: part I. Diagnosis, prognosis and measurements of diastolic function. Circulation 105 (2002) 1387-1393
17. Zile M.R., Gaasch W.H., and Carroll J.D. Heart failure with normal ejection fraction: is measurement of diastolic function necessary to make the diagnosis of diastolic heart failure?. Circulation 104 (2001) 779-782
18. Goicoechea M.J., Beaumont J., González A., López B., Querejeta R., Larman M., et al. Altered cardiac expression of peroxisome prolifierator activated receptor isoforms in patients with hypertensive heart disease. Cardiovasc Res 69 (2006) 899-907
19. Ravassa S., López B., González A., Querejeta R., Larman M., and Díez J. Annexin A5 is a marker of cardiomyocite apoptosis and systolic dysfunction in heart failure of hypertensive origin [resumen]. Circulation 114 (2006) 48
20. Garg S., Narula J., and Chandrashekar Y. Apoptosis and heart failure: clinical relevance and therapeutic target. J Mol Cell Cardiol 21 (2006) 288-294
21. Morissette M.R., and Rosenzweig A. Targeting survival signaling in heart failure. Cur Opin Pharmacol 5 (2005) 165-170
22. Querejeta R., López B., González A., Sánchez E., Larman M., Martínez- Ubago J.L., et al. Increased collagen type I syntesis in patients with heart failure of hypertensive origin. Relation to myocardial fibrosis. Circulation 110 (2004) 1263-1268
23. López B., González A., Querejeta R., Larman M., and Díez J. Alterations of the pattern of collagen deposition may contribute to the deterioration of systolic function in hypertensive patients with heart failure. J Am Coll Cardiol 48 (2006) 89-96
24. Roig E., and Coca A. Papel del tratamiento antihipertensivo en la prevención de la insuficiencia cardíaca. Rev Esp Cardiol 7 (2007) 22F-33F
25. The ALLHAT investigators. Major outcomes in high risk hypertensive patients randomized to angiotensin converting enzyme inhibitor or calcium channel versus diuretic. JAMA 288 (2002) 2981-2997
26. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. J Heart Lung Transplant 21 (2002) 189-203
27. Anguita M. Esquema general del tratamiento de la insuficiencia cardíaca. In: Anguita M. (Ed). Manual de insuficiencia cardíaca (2003), Sociedad Española de Cardiología, Madrid 123-133
28. Ahmed A., Husain A., Love T.E., Gambassi G., Dell'Italia L.J., and Francis G.S. Heart failure, chronic diuretic use and increase in mortality and hospitalization: an observational study using propensity score methods. Eur Heart J 27 (2006) 1431-1439
29. Faris R., Flather M., Purdell H., Henein M., Poole-Wilson P., and Coats A. Current evidence supporting the role of diuretics in heart failure: a meta-analysis of randomised controlled trials. Int J Cardiol 82 (2002) 149-158
30. Díez J., Querejeta R., López B., González A., Larman M., and Martínez-Ubago J.L. Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation 105 (2002) 2512-2517
31. López B., Querejeta R., González A., Sánchez E., Larman M., and Díez J. Effect of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure. J Am Coll Cardiol 43 (2004) 2028-2035
32. Cosín J., and Díez J. Torasemide in chronic heart failure: results of the TORIC study. Eur J Heart Fail 4 (2002) 507-513
33. López B., González A., Beaumont J., Querejeta R., larman M., and Díez J. Identification of a potential cardiac antifibrotic mechanism of torasemide in patients with chronic heart failure. J Am Coll Cardiol 50 (2007) 859-867
34. Díez J., Coca A., Castro Beiras A., De Teresa E., Conthe P., and Anguita M. Efecto de una nueva formulación de torasemida (liberación prolongada) sobre la fibrosis miocárdica en pacientes hipertensos con insuficiencia cardíaca. Hipertensión 24 Supl. 2 (2007)
35. Roca-Cusachs A., Aracil-Vilar J., Calvo-Gómez C., Vaquer-Pérez, Félix Laporta-Crespo J.V., Rojas-Serrano M.J., Guglietta A., Gropper S., and The Torasemide-PR in Hypertension Clinical Trial Investigators Group Clinical Effects of Torasemide Prolonged Release in Mild-to-Moderate Hypertension: A Randomized Noninferiority Trial Versus Torasemide Immediate Release. Cardiovasc Ther 26 (2008) 91-100 Erratum in: Cardiovasc Ther. 2008; 26: 233